Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Hong Kong's Aptorum Stages $12 Million US IPO for Drug Development

publication date: Dec 18, 2018

Aptorum Group, a preclinical Hong Kong pharma, completed a $12 million IPO on the NASDAQ exchange. The company is developing therapeutic drugs, many of which are based on natural substances, along with surgical robotic devices. It expects to file for approval of at least one of its three lead products in the US, China or the EU by 2021. In the IPO, the company placed 761,419 Class A Shares at a price of $15.80 per share, but in their first trading session, the shares lost 11%, dropping to $14.00. More details....

Stock Symbol: (NSDQ: APM)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.